Edinburgh Molecular Imaging Limited is a research-driven biotechnology company based in Edinburgh, Scotland. Established in 2014 by a team of experienced scientists and clinicians, EM Imaging specializes in the development and application of innovative diagnostic imaging technologies utilizing molecular biology techniques. The company’s core focus lies within the field of oncology diagnostics through targeted biomarker discovery and validation. EM Imaging offers bespoke research services focused on identifying novel biomarkers for early cancer detection and monitoring treatment response. The company has a strong emphasis on collaborative partnerships with academic institutions, clinical organizations, and pharmaceutical companies to accelerate drug development initiatives. Their expertise encompasses cell culture, molecular cloning, high-throughput screening, and advanced imaging methodologies. Currently operating as an active entity under SC467269, EM Imaging maintains a significant international presence through collaborations and strategic alliances across Europe and North America. The company’s revenue exceeds £15 Million annually, reflecting its robust research portfolio and commitment to innovation within the biotechnology sector. EM Imaging is structured as a limited liability partnership with a Worker (A) rating, signifying skilled worker status.

Edinburgh Molecular Imaging Limited is a research-driven biotechnology company based in Edinburgh, Scotland. Established in 2014 by a team of experienced scientists and clinicians, EM Imaging specializes in the development and application of innovative diagnostic imaging technologies utilizing molecular biology techniques. The company’s core focus lies within the field of oncology diagnostics through targeted biomarker discovery and validation. EM Imaging offers bespoke research services focused on identifying novel biomarkers for early cancer detection and monitoring treatment response. The company has a strong emphasis on collaborative partnerships with academic institutions, clinical organizations, and pharmaceutical companies to accelerate drug development initiatives. Their expertise encompasses cell culture, molecular cloning, high-throughput screening, and advanced imaging methodologies. Currently operating as an active entity under SC467269, EM Imaging maintains a significant international presence through collaborations and strategic alliances across Europe and North America. The company’s revenue exceeds £15 Million annually, reflecting its robust research portfolio and commitment to innovation within the biotechnology sector. EM Imaging is structured as a limited liability partnership with a Worker (A) rating, signifying skilled worker status.